All In Biotech

NDA 216564 · Deproco

Flavalta

Epinephrine Bitartrate, Lidocaine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Mar 19, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

933

108 Phase 3, 77 recruiting

FAERS reports

22

19 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

FLAVALTA solution is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques [see Dosage and Administration (2.2) ]. FLAVALTA solution is a combination of lidocaine, an amide local anesthetic, and epinephrine, an alpha and beta adrenergic agonist indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 19, 2026 Original approval · Type 5 - New Formulation or New Manufacturer Letter
1 products under this application
  • FLAVALTA · EPINEPHRINE BITARTRATE EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML); LIDOCAINE HYDROCHLORIDE 34MG/1.7ML (20MG/ML) · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine Bitartrate" as an intervention, any sponsor and status, largest first.

All 933 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6
  • anaemia3
  • diarrhoea3
  • cytokine release syndrome2
  • dyspnoea2
  • emotional disorder2
  • facial paralysis2
  • fatigue2
  • infusion related reaction2
  • injection site pain2
  • local anaesthetic systemic toxicity2
  • poor quality product administered2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20164
20181
20192
20201
20217
20231
20253
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Deproco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.